distraction using intranasal Midazolam

PreclinicalSmall molecule

distraction using intranasal Midazolam is one of 26 small molecule programs targeting Anxiety. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnxietyActive, not recruiting

AnxietyPreclinical

Active, not recruiting

Competition

Competitive Landscape

165 competitors in Anxiety

#DrugCompanyPhaseTrials

Duragesic

CCephalon

Phase 3

1 2

Centanafadine

Otsuka

Phase 3

1 3

Yohimbine Hydrochloride

UUnknown Sponsor

Phase 3

1 4

Celexa

AbbVie

Preclinical

1 5

Spravato

WWim Janssens

Preclinical

4 6

Campral

FForest Laboratories

Preclinical

2 7

Luvox

SSolvay Pharmaceuticals

Preclinical

2 8

Anerem

AAcacia Pharma Ltd

Preclinical

2 9

Andriol

AAuxilium

Preclinical

1 10

Intelence

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anxiety1 trial

Management of Preoperative Anxiety in Children: Could a Lollipop Be the Solution?

Recruiting·TTunis University·N/A·NCT06670846·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for distraction using intranasal Midazolam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — distraction using intranasal Midazolam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for distraction using intranasal Midazolam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tunis University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTunis University

distraction using intranasal Midazolam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anxiety1 trial

References

Drug Info

Quick Facts

Related News